Cost Opportunity of Polatuzumab Vedotin as First-Line Therapy for DLBCL on Subsequent Treatments - Brazilian Cost Analysis
Author(s)
Samir Nabhan, MSc1, Douglas Castro, Bachelor2, Veronica E. Mata, MBA, MSc, PhD3;
1Hospital de Clínicas de Curitiba – Universidade Federal do Paraná, Curitiba, Brazil, 2F. Hoffman-La Roche, São Paulo, Brazil, 3F. Hoffman-La Roche, Market access & HTA Manager, SAO PAULO, Brazil
1Hospital de Clínicas de Curitiba – Universidade Federal do Paraná, Curitiba, Brazil, 2F. Hoffman-La Roche, São Paulo, Brazil, 3F. Hoffman-La Roche, Market access & HTA Manager, SAO PAULO, Brazil
Presentation Documents
OBJECTIVES: To analyze the direct cost of treating Diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin (Pola-R-CHP) as first line (1L) therapy, CAR T-cell as a second line (2L) treatment, or epcoritamab as a third line (3L) therapy.
METHODS: Quantitative analysis based on an expert panel discussion about the different costs that contribute to the direct medical cost of the treatments. This analysis considered treatment duration based on clinical evidence, along with the medical direct prices of CMED drugs available in July 2024, laboratory exams, hospitalization, monitoring, and treatment of the principal adverse events. The calculations were based on input from the expert panel and a reference patient with a height of 171 centimeters, weight of 70 kg and body surface area of 1,82m2.
RESULTS: The total direct cost of treatment with Pola-R-CHP in 1L DLBCL patients is U$S 84,460.52, with CAR T-cell therapy in 2L is U$S 451,675.63, and with epcoritamab in 3L is U$S 398,986.04. In other words, the cost to treat one patient with CAR T-cell therapy in 2L would cover the treatment of 4.9 patients in 1L with Pola-R-CHP, and the cost to treat one patient with epcoritamab in 3L would cover the treatment of 4.7 patients in 1L with Pola-R-CHP.
CONCLUSIONS: This study demonstrates the potential to treat and cure more patients in 1L with Pola-R-CHP and provide them with a higher likelihood of avoiding progression compared to other treatments. The progression disease rate in 1L with Pola-R-CHP, is 23.3% for DLBCL patients and 16.1% for high-risk patients (ABC diagnosis), compared to 54% with CAR T-cell therapy and 72.2% with epcoritamab. This information could help decision-makers in engaging in evidence-based and value-driven discussions for patients and healthcare systems, promoting greater efficiency and transparency in terms of budget impact and resource allocation.
METHODS: Quantitative analysis based on an expert panel discussion about the different costs that contribute to the direct medical cost of the treatments. This analysis considered treatment duration based on clinical evidence, along with the medical direct prices of CMED drugs available in July 2024, laboratory exams, hospitalization, monitoring, and treatment of the principal adverse events. The calculations were based on input from the expert panel and a reference patient with a height of 171 centimeters, weight of 70 kg and body surface area of 1,82m2.
RESULTS: The total direct cost of treatment with Pola-R-CHP in 1L DLBCL patients is U$S 84,460.52, with CAR T-cell therapy in 2L is U$S 451,675.63, and with epcoritamab in 3L is U$S 398,986.04. In other words, the cost to treat one patient with CAR T-cell therapy in 2L would cover the treatment of 4.9 patients in 1L with Pola-R-CHP, and the cost to treat one patient with epcoritamab in 3L would cover the treatment of 4.7 patients in 1L with Pola-R-CHP.
CONCLUSIONS: This study demonstrates the potential to treat and cure more patients in 1L with Pola-R-CHP and provide them with a higher likelihood of avoiding progression compared to other treatments. The progression disease rate in 1L with Pola-R-CHP, is 23.3% for DLBCL patients and 16.1% for high-risk patients (ABC diagnosis), compared to 54% with CAR T-cell therapy and 72.2% with epcoritamab. This information could help decision-makers in engaging in evidence-based and value-driven discussions for patients and healthcare systems, promoting greater efficiency and transparency in terms of budget impact and resource allocation.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE98
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Value of Information
Disease
SDC: Oncology